---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-017541"
form_type: "8-K"
ticker: "ACH"
cik: "0000075252"
company_name: "ACCENDRA HEALTH INC/VA/"
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:53:10.994007+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale

## Summary
- Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).
- GAAP loss from continuing ops improved to $9.4M from $331.9M in Q4 2024.
- Adjusted net income $16.7M ($0.21/share) vs $25.0M ($0.32) prior year.
- Adj. EBITDA $90M vs $102.5M; free cash flow $18.3M vs $30.1M.
- Completed sale of Products & Healthcare Services on Dec 31, 2025; focusing on cost control and balance sheet.

## SEC filing metadata
- accession: 0001104659-26-017541
- form_type: 8-K
- ticker: ACH
- cik: 0000075252
- company_name: ACCENDRA HEALTH INC/VA/
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/0001104659-26-017541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/omi-20260219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-017541
- JSON: https://secwatch.observer/filing/0001104659-26-017541.json
- Plain text: https://secwatch.observer/filing/0001104659-26-017541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.